Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyCigna Gastric Pacing Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy 0103

    Gastric Pacing/Gastric Electrical Stimulation (GES)

    Customize your policy alerts

    Sign up for Cigna Policy 0103 alerts

    Get alerted when Policy 0103 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of permanent and temporary gastric electrical stimulation (GES) or gastric pacing for intractable nausea and vomiting associated with gastroparesis.

    Policy Summary
    PayerCigna
    PolicyGastric Pacing/Gastric Electrical Stimulation (GES)
    Policy CodePolicy 0103
    Change TypeAnnual review — no material clinical or coverage changes
    Effective DateNov 15, 20261d
    Next Review DateNov 15, 2027
    Key ActionBefore permanent GES or gastric pacing, confirm that pharmaceutical therapy for gastroparesis has failed, is contraindicated, or is intolerable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1Covered clinical indication
    2Medically necessary procedure codes
    5Medically necessary device codes
    2Experimental temporary GES codes
    InvestigationalGES for obesity
    None identifiedTemporary GES FDA approval

    Medical Necessity and Coverage Criteria

    Permanent GES or Gastric Pacing

    Permanent GES or gastric pacing is considered medically necessary when all applicable conditions are met.

    Permanent GES coverage

    • Clinical indication: Intractable nausea and vomiting secondary to gastroparesis

    • Failure of pharmaceutical therapy

      • Pharmaceutical therapy has failed
      • Pharmaceutical therapy is contraindicated
      • Pharmaceutical therapy is intolerable
    • Device use: The permanent device or gastric pacing is provided in accordance with applicable FDA Humanitarian Device Exemption specifications

      The FDA-described Enterra indication is chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology, typically in adults aged 18-70 years; effectiveness for other etiologies or age groups has not been established.

    Not Covered or Unproven GES

    The following services are not covered or are considered experimental, investigational, or unproven.

    Noncovered or unproven services

    • Other indication: GES or gastric pacing is used for any indication other than intractable nausea and vomiting secondary to gastroparesis
    • Temporary GES: Temporary gastric electrical stimulation is provided

    Gastroparesis

    Permanent GES for gastroparesis is reserved for selected refractory cases rather than routine initial therapy.

    Selected refractory gastroparesis: Consideration is limited to selected patients with gastroparesis whose symptoms remain refractory despite optimized medical therapy, with individualized care and shared decision-making.

    The AGA issued a conditional recommendation against routine initial GES; the ACG stated that GES may be considered for humanitarian use in refractory diabetic or idiopathic gastroparesis.

    Obesity

    GES for obesity is investigational and lacks sufficient supporting evidence.

    Obesity indication: GES for obesity, including morbid obesity, remains under investigation; the FDA-registered status is investigational and published evidence is insufficient to support gastric pacing for morbid obesity.

    The SHAPE randomized trial did not demonstrate a statistically significant difference in excess weight loss at 12 months, and longer-term evidence is limited.

    Type 2 diabetes mellitus

    Evidence for GES in obese patients with type 2 diabetes mellitus remains preliminary.

    T2DM indication: GES for obese patients with type 2 diabetes mellitus has been evaluated mainly in small case series, with preliminary suggestions of improved glycemic control or weight loss but insufficient confirmation of safety and effectiveness.

    Additional well-designed randomized controlled trials are needed.

    Temporary gastric electrical stimulation

    Temporary GES is investigational or off-label with limited evidence.

    Temporary GES or percutaneous stimulation has been investigated as a less-invasive trial before permanent implantation, but FDA approval for temporary GES was not identified and some leads or generators have been used off-label.

    Available studies include an uncontrolled cohort and a small randomized placebo-controlled crossover trial with non-significant symptom improvement.

    Gastric electrical stimulation (GES) or gastric pacing is not covered or reimbursable when used for any indication other than intractable nausea and vomiting secondary to gastroparesis.

    Use of GES for obesity remains under investigation. The Transcend Gastric Stimulation System has not been approved by the FDA for obesity.

    GES for obesity using the Transcend Gastric Stimulation System is not FDA approved and remains under investigation.

    Temporary GES using temporary external cardiac pacing leads is off-label because those leads are not FDA approved for temporary gastric stimulation.

    Gastric pacing for morbid obesity is not supported by sufficient evidence in the published scientific literature.

    Covered and Unproven Procedure Codes

    Considered Medically Necessary — CPT CodesCPTCovered
    43881Implantation or replacement of gastric neurostimulator electrodes, antrum, open
    64590Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver
    Considered Medically Necessary — HCPCS CodesHCPCSCovered
    C1767Generator, neurostimulator (implantable), nonrechargeable
    C1778Lead, neurostimulator (implantable)
    L8679Implantable neurostimulator, pulse generator, any type
    L8680Implantable neurostimulator electrode, each
    Considered Medically Necessary — HCPCS CodesHCPCSCovered
    L8688Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension
    Considered Experimental/Investigational/Unproven — Temporary Gastric Electrical StimulationCPTExperimental
    43659Unlisted laparoscopy procedure, stomach
    43999Unlisted procedure, stomach

    Documentation, Billing, and Denial Risk

    Documentation Required

    Document Failed or Intolerable Pharmaceutical Therapy

    Before requesting permanent GES or gastric pacing, document that the patient has intractable nausea and vomiting secondary to gastroparesis and has experienced failure, contraindication, or intolerance of pharmaceutical therapy.

    • Document relevant prokinetic and antiemetic therapy history, including failed, contraindicated, or intolerable treatment.
    • Include the clinical basis for refractory or intractable symptoms.
    Prior Authorization

    Document Medical Necessity and HDE Compliance

    Requests for permanent GES or gastric pacing must document the qualifying indication and compliance with the FDA Humanitarian Device Exemption (HDE) specifications. Coverage is limited to chronic, intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis within the applicable HDE parameters.

    Clinical Background

    Gastroparesis is a chronic disorder of gastric motility in which solids are retained in the stomach without mechanical obstruction. Associated symptoms may include nausea, vomiting, early satiety, bloating, and upper abdominal discomfort; severe cases may involve weight loss, malnutrition, or dehydration.

    Key Terms and Devices

    Gastroparesis
    DefinitionA chronic motility disorder of the stomach characterized by gastric retention of solids in the absence of mechanical obstruction.
    Common causesIdiopathic, diabetic, iatrogenic, and postsurgical causes.
    Typical symptomsEarly satiety, nausea, vomiting, bloating, and upper abdominal discomfort; severe cases may involve weight loss, malnutrition, or dehydration.
    Gastric electrical stimulation (GES)
    DefinitionDelivery of electrical stimuli to the musculature of the gastric wall through electrodes connected to a stimulator device.
    Intended purposeThe intent is to restore effective gastric contractions or reduce symptoms.
    Policy Summary
    PayerCigna
    PolicyGastric Pacing/Gastric Electrical Stimulation (GES)
    Policy CodePolicy 0103
    Change TypeAnnual review — no material clinical or coverage changes
    Effective DateNov 15, 20261d
    Next Review DateNov 15, 2027
    Key ActionBefore permanent GES or gastric pacing, confirm that pharmaceutical therapy for gastroparesis has failed, is contraindicated, or is intolerable.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered and Unproven Procedure CodesDocumentation, Billing, and Denial RiskClinical BackgroundKey Terms and Devices
  1. Document the qualifying gastroparesis etiology, chronic intractable nausea and vomiting, and prior pharmaceutical therapy history.
  2. Verify and document applicable HDE requirements, including use consistent with HDE H990014 specifications.
  3. Effectiveness for other etiologies or age groups has not been established.
    4. Denial Risk

    Other Indications Are Not Covered

    Permanent GES or gastric pacing is not covered or reimbursable when used for indications other than intractable nausea and vomiting secondary to gastroparesis.

    • Do not submit permanent GES or gastric pacing for obesity, morbid obesity, T2DM-related use, or other nonqualifying indications.
    Denial Risk

    Temporary GES Is Not Covered

    Temporary GES is considered experimental, investigational, or unproven and is not covered under the policy.

    • Temporary GES claims may include unlisted laparoscopy or stomach procedure codes, such as CPT 43659 or 43999, but these services remain experimental, investigational, or unproven when reported for temporary gastric electrical stimulation.
    Billing Rule

    Unmet Criteria or Unsupported Coding May Result in Denial

    Requests or claims that do not satisfy the medical-necessity criteria, or that are submitted without applicable covered procedure and diagnosis coding, may be denied as not covered.

    • Submit the most appropriate codes in effect on the date of service.
    • Ensure the diagnosis and procedure codes support the covered indication and requested service.
    Denial Risk

    Obesity Indication Remains Investigational

    Evidence is insufficient to support GES or gastric pacing for obesity or morbid obesity. Use for this indication remains investigational.

    • The Transcend gastric stimulation system has not been approved by the FDA for obesity.
    • Published studies are limited by small samples, lack of randomization, and short-term follow-up.
    Note

    Insufficient Evidence for T2DM-Related Use

    Evidence supporting GES for obese patients with type 2 diabetes is limited to preliminary, small case series and is insufficient to establish effectiveness.

    • Reported studies included small patient populations and primarily six- to 12-month follow-up.
    • Well-designed randomized controlled trials are needed to confirm effects on glycemic control and weight.
    • The ADA reports that available data are very limited and do not support gastric stimulation as an effective therapy in diabetic gastroparesis.
    Denial Risk

    Temporary GES Lacks Established Regulatory and Evidence Support

    Temporary GES lacks established regulatory approval and sufficient clinical evidence for the indication. FDA approval for temporary gastric electrical stimulation was not identified, and use of temporary external or cardiac pacing leads may be off-label.

    • The Enterra II Neurostimulator's listed compatible lead is an intramuscular lead designed for implantation in the stomach muscle; temporary external leads designed primarily for cardiac pacing are not FDA-approved for temporary GES.
    • Both lead and generator components were used off-label in the cited temporary GES study.
    • Published evidence is sparse and includes uncontrolled or small studies with limitations; well-designed randomized controlled trials are needed.
    Clinical useGES has been proposed for patients with gastroparesis who are refractory to medical treatment.
    Humanitarian Device Exemption (HDE)
    DefinitionA U.S. FDA regulatory pathway for devices intended for rare diseases or conditions.
    Risk-benefit requirementThe device must not pose an unreasonable risk, and probable benefits must outweigh risks compared with available alternatives.
    Enterra Therapy System identifierHDE Number H990014.
    Temporary GES (tGES)
    DefinitionTemporary gastric electrical stimulation using endoscopically placed nonsurgical leads connected to an external gastric stimulation device.
    PlacementThe temporary leads are placed endoscopically on the gastric mucosa.
    Regulatory statusFDA approval for temporary gastric electrical stimulation was not found; temporary external leads may be used off-label.
    Temporary percutaneous GES (TPGES)
    DefinitionTemporary percutaneous gastric electrical stimulation using two percutaneous unipolar leads inserted through a plastic cannula and anchored to submucosal tissue.
    Lead anchoringFlexible wing-like tines anchor the leads to the submucosal tissue.
    Clinical useTPGES has been investigated as a less-invasive trial before permanent GES insertion.
    Enterra II Neurostimulator
    DefinitionA permanently implanted neurostimulator system with a pulse generator placed beneath the skin in the lower abdominal region.
    Electrical deliveryThe neurostimulator generates electrical pulses delivered by implanted leads in the antrum portion of the stomach muscle wall.
    Compatible leadThe intramuscular lead is listed as compatible with the device and is designed to deliver electrical current to the stomach muscle.
    DIAMOND gastric stimulation device
    DefinitionA gastric electrical stimulation device consisting of three pairs of bipolar electrodes.
    Electrode placementOne pair is attached to the gastric fundus, and two pairs are attached to the anterior and posterior antrum of the stomach.
    Pulse generatorThe electrodes are implanted laparoscopically and connected to a pulse generator inserted into the subcutaneous tissue of the abdomen.